Accuray (ARAY) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
24 Dec, 2025Executive summary
Achieved strong Q2 FY25 results with net revenue up 8% year-over-year to $116.2 million, driven by innovation, operational efficiencies, and expansion in China and Asia Pacific, despite declines in the Americas and EIMEA.
Product revenue grew 19% year-over-year to $61.2 million, with standout performance in China, APAC, and Japan; service revenue declined 1%.
Net income for Q2 was $2.5 million, reversing a $9.6 million loss last year; adjusted EBITDA rose to $9.6 million from $2.0 million.
Gross margin improved to 36.1% from 33.5% year-over-year, aided by China JV margin release and favorable product mix.
Operating expenses decreased 7% year-over-year, mainly from lower R&D and G&A costs following restructuring.
Financial highlights
Q2 net revenue was $116.2 million, up 8% year-over-year; product revenue $61.2 million (up 19%), service revenue $55.0 million (down 1%).
Adjusted EBITDA was $9.6 million, up from $2.0 million in the prior year.
Operating income was $4.7 million, compared to a $4.0 million loss last year.
Gross margin improved to 36.1% from 33.5% year-over-year.
Book-to-bill ratio was 1.3, with order backlog at quarter-end of $463.1 million.
Outlook and guidance
Full-year FY25 revenue guidance raised to $463 million–$475 million; adjusted EBITDA guidance increased to $28.5 million–$31 million.
Guidance assumes minimal tariff impact and a recovering U.S. market in the second half of FY25.
Management expects continued headwinds from inflation, supply chain, and logistics costs impacting margins and net income through FY25.
The company believes it has sufficient liquidity for at least the next 12 months but is monitoring debt covenant compliance.
Latest events from Accuray
- Shelf registration covers resale of 7M shares from warrants tied to recent financing.ARAY
Registration Filing17 Feb 2026 - Revenue and margin guidance cut as China headwinds, tariffs, and financing changes weigh.ARAY
Q2 202617 Feb 2026 - Record Q4 revenue and robust FY25 outlook highlight strong growth and global expansion.ARAY
Q4 20241 Feb 2026 - Growth driven by innovation, emerging markets, and margin expansion, with U.S. recovery expected.ARAY
Jefferies Global Healthcare Conference31 Jan 2026 - FY2025 guidance raised as China growth and service gains offset margin and revenue declines.ARAY
Q1 202516 Jan 2026 - Q3 FY25 revenue up 12%, net loss narrowed, but guidance cut on tariffs; EBITDA improved.ARAY
Q3 202527 Dec 2025 - Resale registration covers 23.4M shares from warrant exercises tied to recent financing.ARAY
Registration Filing16 Dec 2025 - Shareholders will vote on director elections, equity plan increases, pay, and auditor ratification.ARAY
Proxy Filing1 Dec 2025 - Major leadership changes and transformation plan target growth, margin expansion, and agility.ARAY
Proxy Filing1 Dec 2025